Anti-CD73/PD-1 Therapy(Cidara Therapeutics Inc)

N/A

Report date: 2023/12/04 10:52:55

Base Information

Drug NameAnti-CD73/PD-1 Therapy(Cidara Therapeutics Inc)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionAnti-5'-nucleotidaseAnti-PD-1

Targets5'-nucleotidaseProgrammed cell death protein 1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCidara Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCidara Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A